127 related articles for article (PubMed ID: 11522487)
21. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy.
Mukherjee S; Ray S; Thakur RS
Pak J Pharm Sci; 2009 Apr; 22(2):131-8. PubMed ID: 19339221
[TBL] [Abstract][Full Text] [Related]
22. Impact of surfactant properties on oxidative stability of beta-carotene encapsulated within solid lipid nanoparticles.
Helgason T; Awad TS; Kristbergsson K; Decker EA; McClements DJ; Weiss J
J Agric Food Chem; 2009 Sep; 57(17):8033-40. PubMed ID: 19691283
[TBL] [Abstract][Full Text] [Related]
23. Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection.
Asasutjarit R; Lorenzen SI; Sirivichayakul S; Ruxrungtham K; Ruktanonchai U; Ritthidej GC
Pharm Res; 2007 Jun; 24(6):1098-107. PubMed ID: 17385021
[TBL] [Abstract][Full Text] [Related]
24. Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel.
Pandita D; Ahuja A; Lather V; Dutta T; Velpandian T; Khar RK
Pharmazie; 2011 Mar; 66(3):171-7. PubMed ID: 21553646
[TBL] [Abstract][Full Text] [Related]
25. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.
Tho I; Liepold B; Rosenberg J; Maegerlein M; Brandl M; Fricker G
Eur J Pharm Sci; 2010 Apr; 40(1):25-32. PubMed ID: 20172027
[TBL] [Abstract][Full Text] [Related]
26. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters.
Shah B; Khunt D; Bhatt H; Misra M; Padh H
Eur J Pharm Sci; 2015 Oct; 78():54-66. PubMed ID: 26143262
[TBL] [Abstract][Full Text] [Related]
27. Influence of electrolyte and poloxamer 188 on the aggregation kinetics of solid lipid nanoparticles (SLNs).
Wei CC; Ge ZQ
Drug Dev Ind Pharm; 2012 Sep; 38(9):1084-9. PubMed ID: 22181005
[TBL] [Abstract][Full Text] [Related]
28. Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations.
Jansook P; Fülöp Z; Ritthidej GC
Drug Dev Ind Pharm; 2019 Apr; 45(4):560-567. PubMed ID: 30632399
[TBL] [Abstract][Full Text] [Related]
29. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
Martins S; Tho I; Souto E; Ferreira D; Brandl M
Eur J Pharm Sci; 2012 Apr; 45(5):613-23. PubMed ID: 22245538
[TBL] [Abstract][Full Text] [Related]
30. Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability.
Radomska-Soukharev A; Müller RH
Pharmazie; 2006 May; 61(5):425-30. PubMed ID: 16724540
[TBL] [Abstract][Full Text] [Related]
31. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake.
Luo Y; Teng Z; Li Y; Wang Q
Carbohydr Polym; 2015 May; 122():221-9. PubMed ID: 25817662
[TBL] [Abstract][Full Text] [Related]
32. The effect of formulative parameters on the size and physical stability of SLN based on "green" components.
Soddu E; Rassu G; Cossu M; Giunchedi P; Cerri G; Gavini E
Pharm Dev Technol; 2016; 21(1):98-107. PubMed ID: 25331189
[TBL] [Abstract][Full Text] [Related]
33. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures.
Olbrich C; Müller RH
Int J Pharm; 1999 Mar; 180(1):31-9. PubMed ID: 10089289
[TBL] [Abstract][Full Text] [Related]
34. Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
Heider M; Hause G; Mäder K
Eur J Pharm Biopharm; 2016 Dec; 109():194-205. PubMed ID: 27789354
[TBL] [Abstract][Full Text] [Related]
35. Influence of co-surfactants on crystallization and stability of solid lipid nanoparticles.
Salminen H; Helgason T; Aulbach S; Kristinsson B; Kristbergsson K; Weiss J
J Colloid Interface Sci; 2014 Jul; 426():256-63. PubMed ID: 24863791
[TBL] [Abstract][Full Text] [Related]
36. Insights into the protective role of solid lipid nanoparticles on rosmarinic acid bioactivity during exposure to simulated gastrointestinal conditions.
Madureira AR; Campos DA; Oliveira A; Sarmento B; Pintado MM; Gomes AM
Colloids Surf B Biointerfaces; 2016 Mar; 139():277-84. PubMed ID: 26766625
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the digestibility of solid lipid nanoparticles of glyceryl dibehenate produced by two techniques: Ultrasonication and spray-flash evaporation.
Jannin V; Blas L; Chevrier S; Miolane C; Demarne F; Spitzer D
Eur J Pharm Sci; 2018 Jan; 111():91-95. PubMed ID: 28966096
[TBL] [Abstract][Full Text] [Related]
38. Quercetin-Loaded Solid Lipid Nanoparticle Dispersion with Improved Physicochemical Properties and Cellular Uptake.
Vijayakumar A; Baskaran R; Jang YS; Oh SH; Yoo BK
AAPS PharmSciTech; 2017 Apr; 18(3):875-883. PubMed ID: 27368922
[TBL] [Abstract][Full Text] [Related]
39. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application.
Paranjpe M; Finke JH; Richter C; Gothsch T; Kwade A; Büttgenbach S; Müller-Goymann CC
Int J Pharm; 2014 Dec; 476(1-2):41-9. PubMed ID: 25261709
[TBL] [Abstract][Full Text] [Related]
40. Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN).
Wang Y; Deng Y; Mao S; Jin S; Wang J; Bi D
Drug Dev Ind Pharm; 2005 Sep; 31(8):769-78. PubMed ID: 16221611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
